BEDFORD, Mass., June 05, 2023 Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and. | June 5, 2023
Vial Adds Dr Jeffrey Heier of OCB to their Ophthalmology CRO Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Dr. Jeffrey Heier, from Ophthalmic Consultants of Boston (OCB) has joined Vial s Ophthalmology Scientific Advisory Board. Dr. Heier joins the.
Longer-term data from the DERBY and OAKS phase 3 studies showed that pegcetacoplan continued to reduce geographic atrophy lesion growth in patients with GA secondary to age-related macular degeneration.